Melanoma

Showing NaN - NaN of 119

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

Recruiting
  • Endometrial Cancer
  • +8 more
  • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
  • Orlando, Florida
  • +21 more
Feb 2, 2023

Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)

Recruiting
  • Colorectal Carcinoma
  • +21 more
  • Dual X-ray Absorptiometry
  • +2 more
  • Birmingham, Alabama
  • +18 more
Jan 30, 2023

Metastatic Solid Tumors, NSCLC, Melanoma Trial in United States (INBRX-105 - PDL1x41BB antibody, Pembrolizumab)

Recruiting
  • Metastatic Solid Tumors
  • +7 more
  • Scottsdale, Arizona
  • +12 more
Jan 26, 2023

Solid Tumor, Non Small Cell Lung Cancer, Melanoma Trial in Lafayette, Boston, Nashville (AB248, Pembrolizumab)

Recruiting
  • Solid Tumor
  • +4 more
  • AB248
  • Pembrolizumab
  • Lafayette, Indiana
  • +2 more
Jan 25, 2023

Melanoma Trial in United States (CAVATAK, Ipilimumab)

Completed
  • Melanoma
  • Duarte, California
  • +10 more
Jan 12, 2023

Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 12, 2023

Melanoma, Lymphoma, Solid Tumor Trial in Worldwide (Pembrolizumab)

Recruiting
  • Melanoma
  • +4 more
  • Pembrolizumab
  • Aurora, Colorado
  • +18 more
Jan 5, 2023

Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))

Completed
  • Ovarian Cancer
  • +7 more
  • Enapotamab vedotin (HuMax-AXL-ADC)
  • Phoenix, Arizona
  • +40 more
Dec 12, 2022

Solid Tumors, Melanoma, NSCLC Trial in France, Spain, United States (CFT1946, Trametinib)

Recruiting
  • Solid Tumors
  • +4 more
  • Boston, Massachusetts
  • +9 more
Dec 19, 2022

Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)

Active, not recruiting
  • Melanoma
  • +7 more
  • Scottsdale, Arizona
  • +36 more
Dec 22, 2022

NSCLC, Ovarian Cancer, Melanoma Trial in Worldwide (LXH254, PDR001)

Terminated
  • NSCLC
  • +3 more
  • Boston, Massachusetts
  • +17 more
Dec 20, 2022

Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 14, 2022

Melanoma Trial in Worldwide (Dabrafenib, Trametinib, Placebos)

Active, not recruiting
  • Melanoma
  • Birmingham, Alabama
  • +209 more
Nov 14, 2022

Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)

Recruiting
  • Melanoma
  • Nivolumab
  • Nivolumab + Relatlimab Fixed Dose Combination
  • Birmingham, Alabama
  • +185 more
Dec 3, 2022

Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or

Active, not recruiting
  • Melanoma
  • +8 more
  • Los Angeles, California
  • +9 more
Nov 15, 2022

Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)

Terminated
  • Melanoma
  • Talimogene Laherparepvec
  • +2 more
  • Birmingham, Alabama
  • +160 more
Nov 10, 2022

Melanoma Trial in Worldwide (Pembrolizumab, Placebo)

Active, not recruiting
  • Melanoma
  • Pembrolizumab
  • Placebo
  • Tucson, Arizona
  • +158 more
Oct 31, 2022

Genetic Testing, Breast Cancer, Ovarian Cancer Trial in Boston (Video Education, Genetic Counseling)

Recruiting
  • Genetic Testing
  • +8 more
  • Video Education
  • Genetic Counseling
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 31, 2022

Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal

Recruiting
  • Breast Cancer
  • +15 more
  • ATRC-101
  • +2 more
  • Phoenix, Arizona
  • +10 more
Sep 28, 2022

RAS Mutation, NRAS Gene Mutation, Melanoma Trial in Phoenix, Newnan, Zion (OKI-179 + binimetinib)

Recruiting
  • RAS Mutation
  • +2 more
  • OKI-179 + binimetinib
  • Phoenix, Arizona
  • +4 more
Sep 22, 2022

NSCLC, Melanoma Trial in Worldwide (LXH254, LTT462, Trametinib)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Melanoma
  • San Diego, California
  • +31 more
Sep 12, 2022

Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

Recruiting
  • Breast Cancer
  • +15 more
  • Goodyear, Arizona
  • +146 more
Aug 24, 2022

Melanoma Trial in Australia, United States (mRNA-4157, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • mRNA-4157
  • Pembrolizumab
  • Tucson, Arizona
  • +21 more
Aug 23, 2022